Test Environment
  
X Close Window
This healthcare service has 1 current healthcare service locations.
Alberta Blood and Marrow Transplant Program   at
Arthur J.E. Child Comprehensive Cancer Centre
Specialty: Blood and Marrow Transplant
Connect Care Department: CGY ACCC BMT COORDINATION
Estimated time to routine appointment: Not Available
Alberta Health Services - Cancer Care Alberta
SERVICE DESCRIPTION
Provides care and support to people having a blood and marrow transplant.Offers care and support for people having an allogeneic or autologous blood and marrow transplant.
Provides care and support to people having a blood and marrow transplant.Offers care and support for people having an allogeneic or autologous blood and marrow transplant.
ELIGIBILITY REQUIREMENTS
As outlined in the Alberta Blood and Marrow Standard Practice Manual

Alberta CAR T-Cell Therapy Program


Patient Eligibility Criteria for Standard of Care Treatment

Patients being considered for CAR T-cell therapy must meet both the diagnosis (A) and clinical criteria (B) listed below:

1. Patient must have one of the following diagnoses1:
  • Relapsed2 or refractory3 diffuse large B-cell lymphoma (DLBCL) of the following subtypes, after two or more lines of systemic therapy:
    • DLBCL not otherwise specified
    • High grade B-cell lymphoma
    • High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement
    • DLBCL arising from follicular lymphoma
    • Primary mediastinal large B-cell lymphoma (PMBCL)
OR
  • CD19+ B-cell acute lymphoblastic leukemia, up to and including age 25, and one (or more) of the following:
    • Refractory disease
    • Relapse after allogeneic stem cell transplantation (SCT)
    • Ineligible for SCT
    • Second or later relapse
1Diagnoses not specifically included in the Health Canada approved product monographs are not eligible for consideration
2Relapsed disease is defined as partial or complete response to the last line of therapy and subsequent progression
3Refractory disease is defined as progressive or persistent disease as the best response to the last therapy

2. Patient must also meet the following criteria
:
  • No prior adoptive T-cell immunotherapy
  • Clinically stable and expected to remain so through to planned CAR T-cell infusion date with adequate vital organ function and performance status such that patient is expected to tolerate therapy
  • No active CNS disease. Patients with history of CNS disease that has been effectively treated are eligible for CAR T-cell therapy
  • No active uncontrolled hepatitis B, hepatitis C, or HIV infection
  • If prior allogeneic SCT, no evidence of active graft-versus-host-disease or need for ongoing immunosuppression
  • Ineligible for or failed autologous stem cell transplantation (DLBCL patients only)
As outlined in the Alberta Blood and Marrow Standard Practice Manual

Alberta CAR T-Cell Therapy Program


Patient Eligibility Criteria for Standard of Care Treatment

Patients being considered for CAR T-cell therapy must meet both the diagnosis (A) and clinical criteria (B) listed below:

1. Patient must have one of the following diagnoses1:
  • Relapsed2 or refractory3 diffuse large B-cell lymphoma (DLBCL) of the following subtypes, after two or more lines of systemic therapy:
    • DLBCL not otherwise specified
    • High grade B-cell lymphoma
    • High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement
    • DLBCL arising from follicular lymphoma
    • Primary mediastinal large B-cell lymphoma (PMBCL)
OR
  • CD19+ B-cell acute lymphoblastic leukemia, up to and including age 25, and one (or more) of the following:
    • Refractory disease
    • Relapse after allogeneic stem cell transplantation (SCT)
    • Ineligible for SCT
    • Second or later relapse
1Diagnoses not specifically included in the Health Canada approved product monographs are not eligible for consideration
2Relapsed disease is defined as partial or complete response to the last line of therapy and subsequent progression
3Refractory disease is defined as progressive or persistent disease as the best response to the last therapy

2. Patient must also meet the following criteria
:
  • No prior adoptive T-cell immunotherapy
  • Clinically stable and expected to remain so through to planned CAR T-cell infusion date with adequate vital organ function and performance status such that patient is expected to tolerate therapy
  • No active CNS disease. Patients with history of CNS disease that has been effectively treated are eligible for CAR T-cell therapy
  • No active uncontrolled hepatitis B, hepatitis C, or HIV infection
  • If prior allogeneic SCT, no evidence of active graft-versus-host-disease or need for ongoing immunosuppression
  • Ineligible for or failed autologous stem cell transplantation (DLBCL patients only)
Referral instructions for primary care, community care, private
providers etc. who do not send referrals via Connect Care. 
REFERRAL PROCESS - FOR NON-CONNECT CARE USERS
Complete the referral form and fax it to the service using the contact information in this profile.
Complete the referral form and fax it to the service using the contact information in this profile.
REFERRAL PROCESS - FOR CONNECT CARE USERS
Send an Internal Referral using the Ambulatory Referral Order to Blood and Marrow Transplant, type CGY ACCC BMT COORDINATION in the “To Department” section and complete order.  
Send an Internal Referral using the Ambulatory Referral Order to Blood and Marrow Transplant, type CGY ACCC BMT COORDINATION in the “To Department” section and complete order.  
ADDITIONAL SERVICE DETAILS
Additional information for the Alberta Blood and Marrow Transplant Clinic may be found in the relevant section of the AHS Cancer Guidelines - Information for Health Professionals.
Please note that the patient must be notified prior to submission of referral to the Arthur Child

ABMTP Referral Triage Guidelines

URGENT
Allogeneic Transplant
  • Relapsed acute leukemia in remission
  • High cytogenetics risk acute leukemia
  • Acute leukemia requiring >1 cycle chemotherapy to achieve remission
  • CMML-2 or RAEB-2, CML AP or CP2
  • MDS with evidence of transformation
  • Myelofibrosis in transformation
  • Severe aplastic anemia
Autologous Transplant
  • Lymphoblastic or Burkitt lymphoma
  • Relapsed Hodgkins lymphoma
  • Relapsed aggressive lymphoma
*Approximate time to transplant (once a donor is identified, if applicable) - Within 8 weeks

CAR T-cell Therapy
  • * see eligibility requirement *
*Approximate time to CAR T infusion - Within 4-6 weeks
SEMI URGENT
Allogeneic Transplant
  • Acute leukemia in first complete remission without high-risk cytogenetics
  • Transfusion-dependent MDS
  • Acute leukemia not in remission
  • Lymphoblastic or Burkitt lymphoma
Autologous Transplant
  • Multiple myeloma
  • Relapsed indolent lymphoma
  • Acute leukemia in remission
  • Relapsed germ cell tumour
*Approximate time to transplant (once a donor is identified, if applicable) - Within 8 - 16 weeks
ROUTINE
Allogeneic Transplant
  • CCL or indolent NHL
  • Hodgkin lymphoma
  • Multiple myeloma
  • Chronic myeloid leukemia, resistant or intolerant to TKI’s
Autologous Transplant
  • Severe autoimmune diseases: Crohn’s, Scleroderma, Multiple sclerosis
*Approximate time to transplant (once a donor is identified, if applicable) - >16 weeks
Additional information for the Alberta Blood and Marrow Transplant Clinic may be found in the relevant section of the AHS Cancer Guidelines - Information for Health Professionals.
Please note that the patient must be notified prior to submission of referral to the Arthur Child

ABMTP Referral Triage Guidelines

URGENT
Allogeneic Transplant
  • Relapsed acute leukemia in remission
  • High cytogenetics risk acute leukemia
  • Acute leukemia requiring >1 cycle chemotherapy to achieve remission
  • CMML-2 or RAEB-2, CML AP or CP2
  • MDS with evidence of transformation
  • Myelofibrosis in transformation
  • Severe aplastic anemia
Autologous Transplant
  • Lymphoblastic or Burkitt lymphoma
  • Relapsed Hodgkins lymphoma
  • Relapsed aggressive lymphoma
*Approximate time to transplant (once a donor is identified, if applicable) - Within 8 weeks

CAR T-cell Therapy
  • * see eligibility requirement *
*Approximate time to CAR T infusion - Within 4-6 weeks
SEMI URGENT
Allogeneic Transplant
  • Acute leukemia in first complete remission without high-risk cytogenetics
  • Transfusion-dependent MDS
  • Acute leukemia not in remission
  • Lymphoblastic or Burkitt lymphoma
Autologous Transplant
  • Multiple myeloma
  • Relapsed indolent lymphoma
  • Acute leukemia in remission
  • Relapsed germ cell tumour
*Approximate time to transplant (once a donor is identified, if applicable) - Within 8 - 16 weeks
ROUTINE
Allogeneic Transplant
  • CCL or indolent NHL
  • Hodgkin lymphoma
  • Multiple myeloma
  • Chronic myeloid leukemia, resistant or intolerant to TKI’s
Autologous Transplant
  • Severe autoimmune diseases: Crohn’s, Scleroderma, Multiple sclerosis
*Approximate time to transplant (once a donor is identified, if applicable) - >16 weeks
COMMUNICATION PROCESS
  • Referral receipt to referring source within 7 days.
  • Acceptance via appointment details or wait list status letter to referring source and patient within 14 days.
  • Appointment outcome to referral source within 30 days.
 
CLICK + TO VIEW REFERRAL GUIDELINES
Routine Reason for Referral
Access Targets convey the clinically appropriate timeframe patients should be seen within, by reason for referral and priority level.
Access Target
Required Information/Investigations
Investigation Timing
Additional Details
Allogeneic transplantation
Medication List (dose, frequency, route)
 
Within 1 month

Past medical history
 
Within 1 month

Bone marrow reports
 
Current

Chemotherapy records (include induction, consolidation and intrathecal)
 
Current

HLA High Resolution Typing (must be performed within the last two years), CMV IgG, ABO Blood Group and Rh Antibody Screen, HLA platelet antibody investigation (applicable for any recipient with possibility of a mismatched donor including haploidentical donor)
 
Current

LDH
 
At diagnosis and latest results

Medication list (dose, frequency, route)
 
Current

Pathology reports
 
Current

Race: If patient's parents are from more than one of the following groups, indicate all) i.e. Caucasian/White; Black; East Indian; Asian/Pacific Islander; Hispanic; Native North American; Unknown; Other - please indicate
 
Current

Radiation therapy records
 
Current

Radiology reports (CT, PET, CXR, u/s, echo etc)
 
Current

Recent blood work (include hematology, coagulation, chemistry and virology
 
Current

Results for HLA typing (if done) including all typing results: patient and siblings (match or not)
 
Current
See Routine Referral Process for ABMTP Referral Triage Guidelines

• Under no circumstances should Human Leukocyte Antigen (HLA) typing requisitions be handed out to the recipient for distribution to family members. This will be coordinated by an Intake Coordinator who will complete legislation and accreditation requirements surrounding sibling typing as required by authoritative bodies.

Autologous transplantation
Medication List (dose, frequency, route)
 
Within 1 month

Past medical history
 
Within 1 month

Bone marrow reports
 
Current

Chemotherapy records (include induction, consolidation and intrathecal)
 
Current

LDH
 
At diagnosis and latest results

Medication list (dose, frequency, route)
 
Current

Pathology reports
 
Current

Radiation therapy records
 
Current

Radiology reports (CT, PET, CXR, u/s, echo etc)
 
Current

Recent blood work (include hematology, coagulation, chemistry and virology
 
Current
See Routine Referral Process for ABMTP Referral Triage Guidelines

CAR-T (chimeric antigen receptor T-cell) therapy
Medication List (dose, frequency, route)
 
Within 1 month

Past medical history
 
Within 1 month

Bone marrow reports
 
Current

Chemotherapy records (include induction, consolidation and intrathecal)
 
Current

LDH
 
At diagnosis and latest results

Medication list (dose, frequency, route)
 
Current

Pathology reports
 
Current

Radiation therapy records
 
Current

Radiology reports (CT, PET, CXR, u/s, echo etc)
 
Current

Recent blood work (include hematology, coagulation, chemistry and virology
 
Current
CAR T-cell Therapy

See Routine Referral Process for ABMTP Referral Triage Guidelines

HLA tissue typing
Medication List (dose, frequency, route)
 
Within 1 month

Past medical history
 
Within 1 month
• Referrals to ABMTP for HLA typing should be for the purpose of allogeneic transplant investigations. ABMTP does not accept referrals for HLA typing for general purposes or for investigations surrounding sibling typing for patients not under care of ABMTP. 

Patient referral for consultation
Medication List (dose, frequency, route)
 
Within 1 month

Past medical history
 
Within 1 month

Bone marrow reports
 
Current

Pathology reports
 
Current

Radiology reports (CT, PET, CXR, u/s, echo etc)
 
Current

Recent blood work (include hematology, coagulation, chemistry and virology
 
Current

Treatment history (chemotherapy and radiation records - if applicable)
 
Current
CONSULTATION ONLY
PATIENT APPOINTMENT INFORMATION
 
MISSED APPOINTMENT GUIDELINES
If you are unable to attend a scheduled appointment, please contact the clinic a minimum of 48 hours in advance.
 
Inactive referrals shall be exited, with commmunciation to the referring physician, from the ABMTP program if no acivity has occurred for greater than 6 months.  Patients may be re-referred to the program at any time if deemed appropriate. 
If you are unable to attend a scheduled appointment, please contact the clinic a minimum of 48 hours in advance.
 
Inactive referrals shall be exited, with commmunciation to the referring physician, from the ABMTP program if no acivity has occurred for greater than 6 months.  Patients may be re-referred to the program at any time if deemed appropriate. 
 
HOURS OF OPERATION
Monday: 8:15 am - 4:30 pm
Tuesday: 8:15 am - 4:30 pm
Wednesday: 8:15 am - 4:30 pm
Thursday: 8:15 am - 4:30 pm
Friday: 8:15 am - 4:30 pm
Description:
Closed on stat holidays
   
 
ADDRESS
3395 Hospital Drive NW
Calgary Alberta
T2N 5G2
PATIENT APPOINTMENT INSTRUCTIONS
  • Bring your Alberta health care card and a piece of government issued photo ID.
  • Check in at reception 15 minutes prior to your scheduled appointment time.
  • You may bring a family member or significant other during your consultation.
  • Please make sure to have someone with you if you are unable to communicate in English
  • Bring your Alberta health care card and a piece of government issued photo ID.
  • Check in at reception 15 minutes prior to your scheduled appointment time.
  • You may bring a family member or significant other during your consultation.
  • Please make sure to have someone with you if you are unable to communicate in English
 
DIRECTIONS
  • If approaching from the east, use the East Site Entrance off 29th Street NW.
  •  If approaching from the west, use the Hospital Drive turn-off from 16th Avenue
  • If approaching from the east, use the East Site Entrance off 29th Street NW.
  •  If approaching from the west, use the Hospital Drive turn-off from 16th Avenue
 
PHONE
587-231-3100
 
PARKING INSTRUCTIONS
The closest parking option is located in the underground parking lot of the Arthur Child, directly off of Hospital Drive. Paid parking is available.
The closest parking option is located in the underground parking lot of the Arthur Child, directly off of Hospital Drive. Paid parking is available.
 
EMAIL
VIRTUAL APPOINTMENT INFORMATION
 
 
WHEELCHAIR ACCESSIBILITY
Yes

The primary purpose of the All Locations list is to let the user easily access any location of a healthcare service without going back to the main search screen.

The locations listed have 3 background colors:
  • Green means the healthcare service@location has referral information attached to it.
  • Brown means the healthcare service@location never had referral information attached to it, or it has unpublished referral information.
  • Red means
    • IA changed the healthcare service@location's status to something other than Current
    • It was deleted if it is an ARD healthcare service@location.
Green  and Brown are always at the top of the list. These are the Healthcare Service@Locations with the status of Current.
The Red list at the bottom consists of non-current Healthcare Service@locations that once had Published referral information in the ARD.
If the referral information was never published in ARD the Healthcare Service@location will not show in the Red list.

The secondary purpose of the All Locations list is to allow ARD Administrators to recover (copy) referral information from the non-current Healthcare Service@Locations to ones that are current.

Common Scenario:
A Healthcare Service moves from one location to another. In this case the IA Healthcare Service@Location record will be made defunct (non-current) and a new Healthcare Service@Location record will be created with a current status. In this scenario the captured referral guidelines in ARD can become "orphaned" as they are not attached to any current IA healthcare service.

Categories of non-current or orphaned referral guidelines: INDIVIDUAL and COMMON.
The REFERRAL GUIDELINES section of the profile has the prefix INDIVIDUAL or COMMON to help you choose the method below when transferring referral guidelines from a non-current Healthcare Service@Location to a current healthcare service@location.

Individual referral process
  1. Click on a non-current (Red) Healthcare Service@Location at the bottom of the All Locations list.
  2. The non-current referral info is displayed with the link Copy this Referral Process to another Healthcare Service@Location link on the upper right hand corner. Click on the copy link.
  3. Choose a current location (Green or Brown) from the All Locations list. This will be the Healthcare Service@Location you are pasting the referral info into.
  4. The system will display the Edit Referral Info screen populated with the referral info from the non-current Healthcare Service@Location you viewed in the first step.
  5. Click Save and the referral info is transferred from the non-current Healthcare Service@Location to the current one.
  6. Repeat these steps for each Healthcare Service@Location that needs attention.

Common referral process - 2 sub cases.
Case 1: At least 1 current Healthcare Service@Location with common referral info is with current status for this healthcare service; One or more Healthcare Healthcare Service@Locations where replaced by new one.
  1. Click on any current Healthcare Service@Location whether it has referral info (Green) or not (Brown).
  2. The healthcare service location opens in the Edit Referral Info screen populated with the current common referral info.
  3. Save it. 
  4. All locations will be updated with the common referral information, including all the locations that don't have referral info yet (Brown). The non-current referrals (Red) will also be updated.
Case 2:  All Healthcare Healthcare Service@Locations for a healthcare service are set to a non-current status and replaced by new ones. In this case there is no current additional referral info to copy from, so the only alternative is to pick up the non-current common referral process (Red). Follow the steps described in the section Individual Referral Process above to copy/paste the non-current common referral info to the current healthcare service locations.
Generally we want to replicate current common referral info to new or replaced healthcare service locations. We only resort to copying non-current common referral info if there is no other option.

Remember: Some fields can be location specific with the common referral process:
Parking Instructions, Directions, Parking Map, Wait Time, Referral Phone or Referral Fax.
To update these items you have to edit each Healthcare Service@Location separately.

ADDITONAL NOTES:
  • The info icon after the All Locations drop down will be visible to ARD Administrators.
  • The system doesn't allow you to copy referral information from one non-current Healthcare Service@Location to another.

 

V6.5